GSDMD and myocardial infarction: MCC950 inhibited inflammation in early myocardial infarction, reduced cardiac fibrosis, and protected cardiac function (105), combined with Rosuvastatin (RVS), MCC950 inhibited the expression of NLRP3, Caspase-1, interleukin-1β, and Gasdermin D n-terminal domains, and decreased serum lactate dehydrogenase (LDH) level, improved cardiac systolic function and myocardial fibrosis in mice (106).